Skip to Main Content

Author Details

David A Rizzieri
Duke University Medical Center
1995
247
56
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37935977A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.Leukemia2024
36657101Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.Cancer Invest2023
37571998Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.Leuk Lymphoma2023
35443559The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.Haematologica2023
37089296Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.Heliyon2023
37134306A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.Blood Adv2023
37129971Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD.JCI Insight2023
36477975Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.Blood Adv2023
36399715North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.Blood2023
36779595Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.Haematologica2023
36577483A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.Transplant Cell Ther2023
34547770Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.Blood Adv2022
35738590Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.In Vivo2022
35727174Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).Leuk Lymphoma2022
35668193P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.Nat Cancer2022
35820082Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.J Clin Oncol2022
35816393Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies.Mycoses2022
36182986Revisiting a single day salvage conditioning following graft failure.Bone Marrow Transplant2022
35046058Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.Clin Cancer Res2022
35081472Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.Transplant Cell Ther2022
35024768Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.JAMA Oncol2022
34551064Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.Blood Adv2022
34667271Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant2022
32624583Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.Bone Marrow Transplant2021
33830035Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients.Transplant Cell Ther2021
33514658Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells.Mol Cancer Res2021
33785862Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.Leukemia2021
33864019Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.Bone Marrow Transplant2021
33781532Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation.Transplant Cell Ther2021
33775617Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.Transplant Cell Ther2021
33724305Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.Blood Adv2021
33632668A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Clin Lymphoma Myeloma Leuk2021
34643126Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Cancer Invest2021
34403791Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.Transplant Cell Ther2021
34428556Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.Transplant Cell Ther2021
34424530Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).Cancer2021
34507002Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.Transplant Cell Ther2021
33994546Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.Blood Cancer J2021
33991725Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.Transplant Cell Ther2021
34017072Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.Bone Marrow Transplant2021
34351368Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.Blood2021
33934351A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.Cancer2021
34146734Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation.Transplant Cell Ther2021
34170918A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.PLoS One2021
34088982Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.Leukemia2021
34333962Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.Haematologica2021
33085090Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.Cancer2021
33422470A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.Clin Lymphoma Myeloma Leuk2021
31558669Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.Haematologica2020
34109316An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia.Nat Cancer2020
  • 1 - 50 of 247

Recommended Authors

Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Career Start Year 2014
Number of shared co-authors 19
Sawa Ito
University of Pittsburgh
Career Start Year 2013
Number of shared co-authors 4
Prapti Patel
The University of Texas Southwestern Medical Center
Career Start Year 2009
Number of shared co-authors 12
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 4
Uma Borate
The Ohio State University
Career Start Year 2008
Number of shared co-authors 19
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 8
Aarthi Shenoy
MedStar Washington Hospital Center
Career Start Year 2006
Number of shared co-authors 3
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 14
Laura F Newell
Oregon Health and Science University
Career Start Year 2003
Number of shared co-authors 12
Eneida R Nemecek
Oregon Health Sciences University
Career Start Year 2002
Number of shared co-authors 6
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 6
Ivan Pasic
Princess Margaret Cancer Centre
Career Start Year 2001
Number of shared co-authors 0
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 12
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Career Start Year 1998
Number of shared co-authors 16
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 18
Wendy Hu
The University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 2
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 16
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 8
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 7
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 8
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 13
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 33
Sima Jeha
St. Jude Children's Research Hospital
Career Start Year 1988
Number of shared co-authors 10
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 6
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 9
Denis-Claude Roy
Universite de Montreal
Career Start Year 1985
Number of shared co-authors 4
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 24
Dietger Niederwieser
University of Leipzig
Career Start Year 1982
Number of shared co-authors 15
Kenneth B Miller
Tufts Medical Center
Career Start Year 1981
Number of shared co-authors 4
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 1

Collaborators

Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 14
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 12
Richard T Maziarz
Oregon Health & Science University
Co-authored papers 11
Jorge Cortes
Georgia Cancer Center
Co-authored papers 8
John T Schiller
David Geffen School of Medicine at university of california los angeles
Co-authored papers 8
David J Adams
Wellcome Sanger Institute
Co-authored papers 8
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 8
Ravi Vij
Co-authored papers 6
Joanne Kurtzberg
Marcus Center for Cellular Cures, Duke University School of Medicine
Co-authored papers 5
Clayton A Smith
University of Colorado, Aurora CO.
Co-authored papers 5
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Co-authored papers 5
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 4
Vivian G Oehler
Fred Hutchinson Cancer Center.
Co-authored papers 4
Lohith Gowda
Yale Cancer Center and Yale School of Medicine
Co-authored papers 4
Adam J Bass
Co-authored papers 4
Gautam Borthakur
MD Anderson Cancer Center
Co-authored papers 4
Veronica Clavijo Jordan
Harvard Medical School
Co-authored papers 4
Steven Z Pavletic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 3
Kikkeri N Naresh
Fred Hutchinson Cancer Research Center
Co-authored papers 3
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 3
Jean-Pierre J Issa
Fels Cancer Institute for Personalized Medicine, Temple University School of Medicine
Co-authored papers 3
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 3
John F DiPersio
Washington University School of Medicine
Co-authored papers 3
Roman Sasik
Center for Computational Biology & Bioinformatics (CCBB), University of California
Co-authored papers 3
Andrew M Evens
Rutgers Robert Wood Johnson Medical School
Co-authored papers 3
Kris C Wood
Duke University
Co-authored papers 2
Kevin H Lin
Duke University
Co-authored papers 2
Ronan Swords
Oregon Health and Science University
Co-authored papers 2
Timothy S Pardee
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Co-authored papers 2
Gary Hardiman
Institute for Global Food Security, Queen's University Belfast
Co-authored papers 2
Release 1.2